SIWA Therapeutics

Executive Summary

SIWA Therapeutics is a preclinical-stage biotechnology company developing novel antibody therapies that selectively eliminate senescent cells, which accumulate with age and drive age-related diseases. Founded in 2020 and headquartered in San Diego, the company's lead candidate, SIWA318H, targets advanced glycation end products (AGEs) expressed on the surface of senescent cells. By clearing these cells, SIWA aims to address a broad range of conditions including fibrosis, osteoarthritis, and neurodegenerative disorders. The company's approach leverages the growing field of senolytics, with SIWA318H designed as a monoclonal antibody that induces antibody-dependent cellular cytotoxicity (ADCC) to specifically remove senescent cells while sparing healthy tissues. As a private, early-stage entity, SIWA Therapeutics faces significant scientific and regulatory risks typical of preclinical biotech. The company has not yet disclosed funding rounds or partnership deals, and its pipeline currently consists of a single candidate. However, the senolytic space has attracted substantial interest from larger pharmaceutical companies, and SIWA's unique targeting mechanism may offer differentiation. Upcoming milestones include IND-enabling studies and potential first-in-human trials, which will be critical for validating the platform. The company's success hinges on demonstrating safety and efficacy in preclinical models and securing additional capital to advance into the clinic.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for SIWA318H60% success
• Q3 2026Presentation of Preclinical Efficacy Data at Major Conference70% success
• Q4 2026Series A or B Financing Round50% success